DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9z7crx/typhoid_fever) has announced the addition of the "Typhoid Fever - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Typhoid Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Typhoid Fever and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Chongqing Zhifei Biological Products Co., Ltd.
- GlaxoSmithKline Plc
- Prokarium Limited
- Protein Potential, LLC
- Shantha Biotechnics Limited
- USV Limited
- Zydus Cadila Healthcare Limited
Drug Profiles
- (typhoid fever + shigellosis) multivalent vaccine
- Typhella
- Typhetec
- typhoid + paratyphoid (bivalent) vaccine
- typhoid + paratyphoid vaccine
- typhoid + pneumococcal vaccine
- typhoid and paratyphoid fever vaccine
- typhoid fever polysaccharide vaccine
- typhoid vaccine
- ViCRM-197
For more information visit http://www.researchandmarkets.com/research/9z7crx/typhoid_fever
